Navigation Links
Celecoxib may prevent lung cancer in former smokers
Date:7/5/2011

PHILADELPHIA Celecoxib may emerge as a potent chemopreventive agent for lung cancer, according to a recent study in Cancer Prevention Research, a journal of the American Association for Cancer Research.

Researchers tested celecoxib, a COX-2 inhibitor, among patients who were former smokers and found a significant benefit in bronchial health as measured by the Ki-67 labeling index, a marker of cellular proliferation or growth, as well as a number of other biomarkers. The findings follow a previous report published in Cancer Prevention Research that showed a similar effect on Ki-67 among former smokers and current smokers (Kim et al., Feb. 2010).

"Taken together, these findings strongly suggest that celecoxib can be used as a chemopreventive agent in these high-risk groups," said Jenny Mao, M.D., a professor of medicine at the University of New Mexico and section chief of pulmonary and critical care medicine at the New Mexico VA Health System.

Mao cautioned, however, that both the current study, where she was the lead researcher, and the Feb. 2010 study were phase II trials, and that large phase III trials are still needed to confirm the findings.

J. Jack Lee, Ph.D., a professor of biostatistics at The University of Texas M. D. Anderson Cancer Center and the statistical editor of Cancer Prevention Research, estimates that there are currently 45 million former smokers and 45 million current smokers in the United States alone.

"The oncology community does not have a good treatment for lung cancer. Unless it is caught in the earliest stages, the five-year survival is only about 15 percent," said Lee. "The best way is to intercept at the earliest stages and try to reverse the processes that can lead to cancer. These studies suggest celecoxib may be a tool to do that."

For the current study, Mao and colleagues enrolled 137 patients and randomly assigned them to 400 mg celecoxib twice daily or a placebo. Patients had to be at least 45 years old, and had to have stopped smoking for at least a year.

Researchers conducted bronchoscopies at baseline and six months to measure changes in the Ki-67 labeling index. Treatment with celecoxib reduced this index by 34 percent compared to a 3.8 percent increase with the placebo group. Decreases in this index were also linked with a reduction in lung nodules, a potential precursor to cancer.


'/>"/>

Contact: Jeremy Moore
jeremy.moore@aacr.org
267-646-0557
American Association for Cancer Research
Source:Eurekalert

Related biology news :

1. Study: Preventive use of one form of natural vitamin E may reduce stroke damage
2. Bone loss prevention experiment on the last space shuttle flight
3. Preventing diabetes damage: Zincs effects on a kinky, two-faced cohort
4. Alzheimers prevention in your pantry
5. Lithium profoundly prevents brain damage associated with Parkinsons disease
6. Using olive oil in your diet may prevent a stroke
7. USC: Active social, spiritual and physical life helps prevent health decline in seniors
8. Using magnets to help prevent heart attacks
9. Pregnant women can prevent excess weight gain with simple steps, study finds
10. Enzyme prevents fatal heart condition associated with athletes
11. UofL infection prevention and control expert to influence national health-care leaders
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/7/2016)... 2016 According to a new market research report "Emotion ... Expression, Voice Recognition), Service, Application Area, End User, And Region - Global Forecast ... USD 6.72 Billion in 2016 to USD 36.07 Billion by 2021, at a ... Reading ... MarketsandMarkets Logo ...
(Date:12/7/2016)... LONDON , Dec. 7, 2016   Avanade ... most successful Formula One teams in history, exploit biometric ... pit stop performance and maintain the competitive edge against ... in 2016. Avanade has worked with ... a range of biometric data (heart rate, breathing rate, ...
(Date:12/6/2016)... -- Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH) (the "Company") ... million principal amount of its 1.414% senior unsecured notes due ... unsecured notes due 2026. The closing of ... to the satisfaction of customary closing conditions.  The notes will ... The Company intends to use the net proceeds from ...
Breaking Biology News(10 mins):
(Date:1/12/2017)... ... January 12, 2017 , ... After her brain cancer ... gave her only a few months to live. Now a paper publishing January ... Rosendahl’s disease and increased both the quantity and quality of her life: Adding ...
(Date:1/12/2017)... PUNE, India , January 12, 2017 The report "Direct-Fed ... Aquatic Animals), Form (Dry and Liquid), and Region - Global Forecast to 2022", ... 934.5 Million in 2016 and projected to reach USD 1,399.6 Million by 2022, ... Reading ... MarketsandMarkets Logo ...
(Date:1/11/2017)... ... January 11, 2017 , ... As a graduate student, Scarlet ... pathogens that cause malaria and tuberculosis. Seeing firsthand the ravages those diseases visit ... as an assistant professor of biology and biotechnology at Worcester Polytechnic Institute (WPI), ...
(Date:1/11/2017)... ... January 11, 2017 , ... ... in clinical settings, it is becoming increasingly clear that the evolution and transmission ... methods, the standard in the study of clinical resistance, has vastly underestimated these ...
Breaking Biology Technology: